Investment Snapshot
-Divi’s Laboratories was started by Dr. Murali k. Divi in the year 1990. Initially , the company was engaged in research and process development. From 1994, it branched into manufacturing, with the first commercial product being the API of Naproxen. Today Divi’s lab is a world known pharmaceutical company with presence in over 100 countries, and long standing relationships with global pharma companies. The competitive edge Divi’s enjoys stems from its chemistry expertise, backward integration, regulatory compliance and top class quality products.
– Divi’s labs market cap stands at approximately Rs.2,20,946 Crore, August 2026
-Headquartered in Hyderabad, India
– Manufacturing facilities – Visakhapatnam (units I and II ) and Kakinada (unit III). The Unit III is undergoing expansion, and the management plans to continue to scale up the expansion in phases.
– Revenue – export oriented , with around 89 % of the revenue being derived from exports (FY26). Serves regulated markets such as the US, Europe, Japan, Asia and more.
– Long standing relationships with leading global innovator and generic pharmaceutical companies, presence in high barrier and regulated markets showcasing resilience, quality and compliance.
-Business Segments
Active Pharmaceutical Ingredients – Manufactures Generic API in high volumes
CDMO (Contract Development and Manufacturing Organization) – Develops and manufactures intermediates and APIs for innovator pharmaceutical companies
Nutraceuticals – vitamin and nutrition ingredients, to meet the growing demand for dietary and supplement market
Competitive Advantages
Leadership in selected APIs
Strong Backward integration
Capacity Expansion and infrastructure
Debt – free balance sheet
Favourable Compliance history, with presence in over a 100 countries
Quality and supply chain dominance
Less dependency on raw material supply
Proven track record of quality and performance
Key risks
Regulatory Actions
Foreign exchange fluctuations
Raw material costs variability
Delay in commercialisation in CDMO projects
Competitive pricing in Generic APIs
Supply chain disruptions and concentration risks
Business Overview
The company started in 1990. It ventured into manufacturing APIs in 1994, and diversified its portfolio across multiple APIs.Today, it manufactures approximately 30 generic APIs, and it is the world’s largest manufacturer of more than 10 of these APIs. Generic APIs are produced in large volumes and sold to pharma companies. With Capacity expansion and infrastructure building , Divi’s subsequently expanded into CDMO business.. CDMO model of revenue enables DIVI’s to make use of its already existing infrastructure, and deliver quality API to innovator Pharmaceutical companies.. One of the greatest advantages of the CDMO business vertical for DIVI’s is, that it does not have to engage into heavy cost Research and Development involved in inventing or discovering unique molecule formulations. The company does have a Research and development vertical, focused mainly on improving yield, speed and efficiency.Divi’s has expanded into the Nutraceticals ingredients business to meet the dietary and nutritional needs of the end customers.
Market outlook
Generic APIs: The global API market is projected to grow from USD 270 billion in 2025 to USD 419 billion by 2033, driven by increasing demand for generic medicines and rising healthcare expenditure.
CDMO: The global CDMO market is expected to expand from approximately USD 150 billion to USD 290–300 billion by the early 2030s, supported by increasing pharmaceutical outsourcing and demand for complex manufacturing.
Peptides: The global peptide therapeutics market is projected to grow from USD 140 billion in 2025 to USD 295 billion by 2033, driven by GLP-1 therapies and increasing adoption of targeted medicines.
Nutraceuticals: The global nutraceuticals market is expected to grow from approximately USD 684 billion in 2026 to USD 1.15 trillion by 2033, supported by growing consumer focus on preventive healthcare and wellness.